期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 8, 期 3, 页码 S5-S16出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2014.02.013
关键词
Statins; Cognition; Memory; Adverse drug effects; Iatrogenesis
资金
- Astra Zeneca
- Pfizer
- Pfizer, Bristol Myers Squibb
- Medisystems Pharmacy
- Remedy's Rx Pharmacies
- NIH [P50 AG025688]
- Amgen
- Bayer Healthcare
- Glaxo-Smith-Kline
- Roche
- Sanofi Aventis
The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors. (C) 2014 National Lipid Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据